ArticleWorld journal of microbiology & biotechnology2025
Statistical optimisation and analysis of biomass and exopolysaccharide production by Lacticaseibacillus rhamnosus LRH30.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Exopolysaccharides (EPS) produced by lactic acid bacteria with immunomodulatory potential are promising natural food additives. This study employs small-scale, 250 mL bioreactors combined with a central composite design to optimise two important bioprocess parameters, namely temperature and airflow, to achieve high yields of biomass and EPS from Lacticaseibacillus rhamnosus LRH30 (L. rhamnosus LRH30). A quadratic model was determined to be the best fit for the production of both products. The optimum critical process parameters for maximised biomass were identified to be 37.01 °C with an airflow of 0.12 vvm, while optimum criteria was 20.1 °C with an airflow of 0.18 vvm for maximum EPS production. Under these optimized conditions, small-scale batch experiments yielded a biomass concentration of 10.1 g/L and an EPS yield of 520.2 mg/L. In comparison, scale-up experiments in 2L reactors resulted in a biomass concentration of 8.54 g/L (a reduction of 18%) and an EPS yield of 654.6 mg/L (an increase of 26%). The produced EPS was purified and characterised through Fourier transform infrared spectroscopy and showed characteristic peaks associated with polysaccharides. The immunomodulatory potential of the L. rhamnosus LRH30 cells and EPS was evaluated through cytokine and chemokine secretion in a J774A.1 murine macrophage, resulting in a predominantly anti-inflammatory effect of L. rhamnosus LRH30 and EPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.